Blood Culture News
-
Accelerate Diagnostics Announces Launch Of Accelerate Arc Module and BC Kit
The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, ...
-
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company, effective June 22, 2022. “As we continue to make progress on pivoting the organization to focus on Core Business execution, we are very ...
-
Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the SeptiCyte® RAPID (developed in collaboration with Immunexpress) and one on the Idylla™ SARS-CoV-2 Test (CE-IVD) and Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD), ...
By Biocartis NV
-
Accelerate Diagnostics completes IVD registration of the Accelerate Arc system with U.S. FDA
Designed for labs with MALDI platforms, the Accelerate Arc Module and BC kit is a novel application of inline centrifugation and automated sample prep techniques, which together with the blood culture (BC) kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. Accelerate Arc system now available as a registered IVD Today we announced the completed ...
-
Specific Diagnostics announces that Nathan Clark, former GenMark Sales Leader, joins Specific Diagnostics as Strategic Account Director, US East
Specific Diagnostics today announced the appointment of Nathan Clark as Strategic Account Director. Nathan was a key member of the GenMark sales leadership team, most recently as a sales manager for GenMark’s Northeast region, overseeing a team of 7 sales professionals and infectious disease specialists responsible for approximately $70M of revenue. Nathan was a critical part of the sales ...
-
New performance data for Accelerate Arc to be presented April 25 at ECCMID
Today we announced the release of new performance data across two studies for the Accelerate Arc module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022. Two posters featuring performance of the Accelerate Arc System will be presented on Monday April 25th, 12:00- 13:00 hr, Pavilion 3 of the Feira ...
-
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
April 25, 2022 at 9:30 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 25, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office (“US PTO”) has granted the patent regarding ...
-
Selux Diagnostics Announces Additional $50 Million in Series C Funding
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation Phenotyping (NGP) rapid Antimicrobial Susceptibility Testing (AST) platform. "This Series C funding allows us to build out our ...
-
Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System
Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin. “We are proud to commercialize the Advance Safety Needle, as there ...
By Kurin, Inc.
-
Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures
Kurin. Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO. The agreement is sole source and is for three years. “AllSpire Health GPO and Kurin are committed to patient safety by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing ...
By Kurin, Inc.
-
Specific Diagnostics Announces the Creation of a European Warehouse and Servicing Center
Specific Diagnostics today announces the opening of its European warehouse and servicing center in Amsterdam, Netherlands, to support its growing European operations. Working with global integrated logistics leader Crane Worldwide Logistics, Specific and its European subsidiary Specific Diagnostics Europe, Ltd., will warehouse Reveal® instruments and consumables in the Amsterdam facility. The ...
-
Magnolia Medical, MHA Solutions, and Healthcare Providers Insurance Company Enter into an Exclusive, Endorsed Agreement for the Steripath Initial Specimen Diversion Device
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance (HPIC), a reciprocal insurer that ...
-
Specific Diagnostics Announces the Formation of its US Commercial Team and Introduction of the Reveal Rapid AST System to the US Market
Specific Diagnostics today announced formation of its US commercial sales, service, support and marketing teams in anticipation of the launch of the Reveal Rapid AST System for blood infection samples. Following 11 studies across France and England comprising over 1,400 clinical positive blood culture samples, yielding overall accuracy of 97.8%, and in tandem with the commencement of clinical and ...
-
Members of Congress Urge CMS to Take Action to Reduce Preventable False-Positive Diagnostic Test Results for Sepsis
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing1, commended U.S. Representatives Mike Levin (D-CA), Gus Bilirakis (R-FL), and eight of their colleagues for sending a joint, bipartisan letter urging the Centers for Medicare and Medicaid Services (CMS), an agency within ...
-
Former Genmark Senior Vice President Scott O’Brien Joins Specific Diagnostics as Chief Commercial Officer
Specific Diagnostics today announced the appointment of Scott O’Brien as its Chief Commercial Officer. Mr. O’Brien is an industry veteran with over 20 years in molecular and infectious disease diagnostics, the last 10 at GenMark where he held a range of commercial positions, most recently Senior Vice President Global Marketing and International Sales at GenMark Diagnostics, ...
-
Specific Diagnostics Announces that David Barreca, former GenMark Sales Leader, Joins Specific as
Specific Diagnostics today announced the appointment of David Barreca as Vice President of US Sales. David was a key member of GenMark’s sales leadership team, most recently a Senior Director managing a team of Account Executives that drove growth of the GenMark infectious disease diagnostics product, contributing the sales growth that led to GenMark’s acquisition by Roche Diagnostics ...
-
Magnolia Medical Announces Expansion of Its Extensive Clinical Evidence Library with Six Steripath® ISDD® Studies in 2021 Demonstrating Zero or Near-Zero False Positive Sepsis Test Results
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced that six studies, reporting zero or near-zero blood culture contamination rates and up to a 31% reduction in vancomycin days of therapy (DOT) using Steripath, were submitted, accepted and published in ...
-
Magnolia Medical Further Strengthens Executive Management Team with the Addition of Silicon Valley Financial Leader, Patrick O’Malley, as Chief Financial Officer
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the expansion of its senior leadership team with the addition of Patrick O’Malley as Chief Financial Officer. Mr. O’Malley is a seasoned public company executive bringing over three decades ...
-
Magnolia Medical Appoints Industry Veteran, Joseph Bishop, as the Senior Vice President of Operations and Product Development
Magnolia Medical Technologies, Inc., inventors of Steripath, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the addition of Joseph Bishop to the executive leadership team as Senior Vice President of Operations and Product Development. Mr. Bishop brings extensive and diverse medical device experience to Magnolia ...
-
Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that it has received a $2.8 million award from the U.S. National Institutes of Health (NIH) to help the company commercialize its Next Generation 'Phenotyping' (NGP) platform for rapid antimicrobial susceptibility testing (AST). Having ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you